CANGENE TO HOST FISCAL 2010 YEAR-END CONFERENCE CALL ON THURSDAY, OCTOBER 28,
2010 AT 11:00 A.M. EASTERN

Listed TSX, Symbol: CNJ

TORONTO AND WINNIPEG, Oct. 25 /CNW/ - Cangene Corporation today announces that it intends to host a conference call on Thursday, October 28, 2010 at 11:00 a.m. Eastern to discuss its financial results for its 2010 fiscal year, ended July 31, 2010.  The Company intends to disclose its financial results via news release after market close on Wednesday, October 27, 2010.

To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191.  The conference call will be archived for replay until Thursday, November 4, 2010, at midnight. To access the archived conference call, dial 416-849-0833 or 1-800-642-1687 and enter the reservation number 19603835 followed by the number sign.

A live audio webcast of the conference call will be available at www.cangene.com and www.newswire.ca.  Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.  The webcast will be archived at the above web sites for 90 days.

About Cangene Corporation

Cangene is one of Canada's largest and earliest biopharmaceutical companies.  It was founded in 1984 and is headquartered in Winnipeg, Manitoba.  Cangene has approximately 800 employees in eight locations across North America and its products are sold worldwide.  It operates three large manufacturing facilities - two in Winnipeg, Manitoba and one in Baltimore, Maryland - where it produces its own products and undertakes contract manufacturing for a number of companies.  Cangene operates three U.S. and one Canadian plasma-collection facilities branded as Cangene Plasma Resources (www.cangeneplasma.com).  In addition, it has a regulatory affairs, sales and corporate communications office in Toronto, Ontario.

Cangene is focused on developing therapeutics for infectious diseases, and the Company uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. Cangene has four FDA and/or Health Canada-approved hyperimmune products.  In addition, the Company has several more products in development at various stages. Three of Cangene's products have been accepted into the U.S. Strategic National Stockpile—botulism antitoxin (investigational product), anthrax immune globulin (investigational product) and vaccinia immune globulin intravenous^™, a product used to counteract certain complications that may arise from smallpox vaccination.  Capitalizing on its drug manufacturing expertise, Cangene also operates a significant contract research and manufacturing business using the resources of Baltimore, Maryland-based Cangene bioPharma, Inc. (a wholly-owned subsidiary; formerly Chesapeake Biological Laboratories, Inc.; www.cangenebiopharma.com).  Cangene's website, www.cangene.com, includes product and investor information, including past news releases.  For more information about Cangene's plasma-collection programs, visit www.cangeneplasma.com.

For further information:

For further information about Cangene Corporation, please contact Jean Compton at [phone] or by email at [email protected]